ArticleBiomolecules & therapeutics2022
Novel GPR43 Agonists Exert an Anti-Inflammatory Effect in a Colitis Model.
Article in Biomolecules & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Gut microbiota metabolites in the immunoregulation of enteritis: research progress.Frontiers in immunology · 2025Pooled it
- Adipocyte-specific FFA2 deletion leads to increased adipose inflammation and is associated with altered intestinal lipid handling in mice.Physiological reports · 2026Article
- The synergistic pro-inflammatory effect of butyric and propionic acid on human periodontal ligament cells via activation of G-protein-coupled receptor 41.Journal of periodontal & implant science · 2026Article
- GPR43 alleviates LPS-induced acute lung injury by inhibiting NLRP3 inflammasome activation via β-arrestin 2.Biology direct · 2026Article
- Harnessing the gut microbiome for precision therapeutics in heart failure.Frontiers in pharmacology · 2026Review
- Article
- The role of ketone bodies in oxidized LDL-induced cell proliferation and lipid accumulation of macrophages.International journal of experimental pathology · 2025Article
- Metabolite-Sensing Receptors: Emerging Targets for Modulating Chronic Pain Pathways.Current issues in molecular biology · 2025Review
- Gut Microbiota Metabolite Messengers in Brain Function and Pathology at a View of Cell Type-Based Receptor and Enzyme Reaction.Biomolecules & therapeutics · 2024Review
- GPR41 and GPR43 regulate CD8Frontiers in immunology · 2024Article
- Intestinal Microbiota and Metabolomics Reveal the Role ofNutrients · 2023Article
- Article
- Gut microbiota short-chain fatty acids and their impact on the host thyroid function and diseases.Frontiers in endocrinology · 2023Review
- The Role of Short Chain Fatty Acids in Irritable Bowel Syndrome.Journal of neurogastroenterology and motility · 2022Review
- Regulatory role of short-chain fatty acids in inflammatory bowel disease.Cell communication and signaling : CCS · 2022Review
- Gut Microflora Modulates Th17/Treg Cell Differentiation in Experimental Autoimmune ProstatitisFrontiers in immunology · 2022Article
- The Beneficial Role of ProbioticFrontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GPR43 (also known as FFAR2), a metabolite-sensing G-protein-coupled receptor stimulated by short-chain fatty acid (SCFA) ligands is involved in innate immunity and metabolism. GPR43 couples with Gα
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.